M42, Abu Dhabi, UAE.
Department of Health (DOH), Abu Dhabi, UAE.
Nat Commun. 2024 Jun 28;15(1):5490. doi: 10.1038/s41467-024-49744-6.
The widespread administration of COVID-19 vaccines has prompted a need to understand their safety profile. This investigation focuses on the safety of inactivated and mRNA-based COVID-19 vaccines, particularly concerning potential cardiovascular and haematological adverse events. A retrospective cohort study was conducted for 1.3 million individuals residing in Abu Dhabi, United Arab Emirates, who received 1.8 million doses of the inactivated BBIBP CorV (by SinoPharm) and mRNA-based BNT162b2 (Pfizer-BioNTech) vaccines between June 1, 2021, and June 30, 2022. The study's primary outcome was to assess the occurrence of selected cardiovascular and haematological events leading to hospitalization or emergency room visits within 21 days post-vaccination. Results showed no significant increase in the incidence rates of these events compared to the subsequent 22 to 42 days following vaccination. Analysis revealed no elevated risk for adverse outcomes following first (IRR 1·03; 95% CI 0·82-1·31), second (IRR 0·92; 95% CI 0·72-1·16) and third (IRR 0·82; 95% CI 0·66-1·00) doses of either vaccine. This study found no substantial link between receiving either mRNA and inactivated COVID-19 vaccines and a higher likelihood of cardiovascular or haematological events within 21 days after vaccination.
广泛接种 COVID-19 疫苗促使人们需要了解其安全性概况。本研究重点关注灭活疫苗和基于 mRNA 的 COVID-19 疫苗的安全性，特别是潜在的心血管和血液学不良事件。对 2021 年 6 月 1 日至 2022 年 6 月 30 日期间居住在阿拉伯联合酋长国阿布扎比的 130 万人进行了回顾性队列研究，他们接种了 180 万剂灭活的 BBIBP CorV（由国药控股）和基于 mRNA 的 BNT162b2（辉瑞-生物科技）疫苗。该研究的主要结局是评估接种疫苗后 21 天内导致住院或急诊的选定心血管和血液学事件的发生情况。结果显示，与接种后第 22 至 42 天相比，这些事件的发生率没有显著增加。分析显示，首次（IRR 1.03；95%CI 0.82-1.31）、第二次（IRR 0.92；95%CI 0.72-1.16）和第三次（IRR 0.82；95%CI 0.66-1.00）接种任何一种疫苗后，不良结局的风险均未升高。本研究发现，接种任何一种 mRNA 和灭活 COVID-19 疫苗与接种后 21 天内发生心血管或血液学事件的可能性增加之间没有实质性联系。
